

# Chemotherapy-Induced Peripheral Neuropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/C44F9394C69BEN.html>

Date: May 2024

Pages: 129

Price: US\$ 6,499.00 (Single User License)

ID: C44F9394C69BEN

## Abstracts

The 7 major chemotherapy-induced peripheral neuropathy markets are expected to exhibit a CAGR of 4.44% during 2024-2034.

The chemotherapy-induced peripheral neuropathy market has been comprehensively analyzed in IMARC's new report titled "Chemotherapy-Induced Peripheral Neuropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chemotherapy-induced peripheral neuropathy (CIPN) is a distressing and often debilitating side effect that can arise as a result of certain cancer treatments. It is characterized by damage to the peripheral nerves, leading to a range of symptoms that significantly impact patients' quality of life. Common indications include tingling, numbness, burning sensations, and weakness in the extremities, particularly in the hands and feet. Individuals suffering from the illness may also experience trouble with coordination, balance, and fine motor skills. The diagnosis of CIPN involves a comprehensive assessment of the patient's medical history, including details of the chemotherapy agents used, dosage, and duration of treatment. The healthcare professional may also conduct clinical examinations, nerve conduction studies, and electromyography to evaluate nerve function and pinpoint the extent of nerve damage. Additionally, patients' self-reported symptoms play a crucial role in diagnosis. It is crucial for physicians to distinguish CIPN from various other potential causes of neuropathy and to tailor treatment strategies accordingly.

The increasing cases of cancer, which requires chemotherapy, causing damage to the nerves by interfering with their structure and function, are primarily driving the chemotherapy-induced peripheral neuropathy market. In addition to this, the inflating utilization of efficacious interventions, including neuroprotective agents, antioxidants,

and nerve growth factor modulators, to effectively mitigate and alleviate the symptoms associated with CIPN is also creating a positive outlook for the market. Moreover, the widespread adoption of physical therapies and lifestyle modifications, as they aid in enhancing nerve function, minimizing discomfort, and ameliorating patients' overall quality of life, is further bolstering the market growth. Apart from this, the rising usage of novel treatments, such as scrambler therapy and dorsal root ganglion stimulation, which target neural pathways and provide relief from neuropathic pain in individuals suffering from the ailment, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of complementary therapies like acupuncture and transcutaneous electrical nerve stimulation to enhance treatment outcomes is also augmenting the market growth. Furthermore, the escalating application of regenerative medicine approaches, encompassing stem cell therapy and gene therapy, to address the root causes of CIPN by rejuvenating damaged nerve tissue and rectifying the genetic anomalies responsible for its onset is expected to drive the chemotherapy-induced peripheral neuropathy market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the chemotherapy-induced peripheral neuropathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chemotherapy-induced peripheral neuropathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chemotherapy-induced peripheral neuropathy market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States  
Germany  
France  
United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the chemotherapy-induced peripheral neuropathy market  
Historical, current, and future performance of various therapeutic categories in the market  
Sales of various drugs across the chemotherapy-induced peripheral neuropathy market  
Reimbursement scenario in the market  
In-market and pipeline drugs  
Competitive Landscape:  
This report also provides a detailed analysis of the current chemotherapy-induced peripheral neuropathy marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of

marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the chemotherapy-induced peripheral neuropathy market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the chemotherapy-induced peripheral neuropathy market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the chemotherapy-induced peripheral neuropathy market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of chemotherapy-induced peripheral neuropathy across the seven major markets?

What is the number of prevalent cases (2018-2034) of chemotherapy-induced peripheral neuropathy by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of chemotherapy-induced peripheral neuropathy by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with chemotherapy-induced peripheral neuropathy across the seven major markets?

What is the size of the chemotherapy-induced peripheral neuropathy patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of chemotherapy-induced peripheral neuropathy?

What will be the growth rate of patients across the seven major markets?

Chemotherapy-Induced Peripheral Neuropathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming

years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for chemotherapy-induced peripheral neuropathy drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chemotherapy-induced peripheral neuropathy market?

What are the key regulatory events related to the chemotherapy-induced peripheral neuropathy market?

What is the structure of clinical trial landscape by status related to the chemotherapy-induced peripheral neuropathy market?

What is the structure of clinical trial landscape by phase related to the chemotherapy-induced peripheral neuropathy market?

What is the structure of clinical trial landscape by route of administration related to the chemotherapy-induced peripheral neuropathy market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (?2018-2034?)
  - 7.2.4 Epidemiology by Gender (?2018-2034?)
  - 7.2.5 Diagnosed Cases (?2018-2034?)
  - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (?2018-2034?)
  - 7.3.4 Epidemiology by Gender (?2018-2034?)
  - 7.3.5 Diagnosed Cases (?2018-2034?)
  - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (?2018-2034?)
  - 7.4.4 Epidemiology by Gender (?2018-2034?)
  - 7.4.5 Diagnosed Cases (?2018-2034?)
  - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (?2018-2034?)
  - 7.5.4 Epidemiology by Gender (?2018-2034?)
  - 7.5.5 Diagnosed Cases (?2018-2034?)
  - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (?2018-2034?)
  - 7.6.4 Epidemiology by Gender (?2018-2034?)
  - 7.6.5 Diagnosed Cases (?2018-2034?)
  - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)

- 7.7.2 Epidemiology Forecast (2024-2034)
- 7.7.3 Epidemiology by Age (?2018-2034?)
- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (?2018-2034?)
  - 7.8.4 Epidemiology by Gender (?2018-2034?)
  - 7.8.5 Diagnosed Cases (?2018-2034?)
  - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (?2018-2034?)
  - 7.9.4 Epidemiology by Gender (?2018-2034?)
  - 7.9.5 Diagnosed Cases (?2018-2034?)
  - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

## **8 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - UNMET NEEDS**

## **10 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - KEY ENDPOINTS OF TREATMENT**

## **11 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - MARKETED PRODUCTS**

- 11.1 List of Chemotherapy-Induced Peripheral Neuropathy Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action



- 11.1.1.3 Regulatory Status
- 11.1.1.4 Clinical Trial Results
- 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

## **12 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - PIPELINE DRUGS**

### 12.1 List of Chemotherapy-Induced Peripheral Neuropathy Pipeline Drugs Across the Top 7 Markets

- 12.1.1 WST-057 - WinSanTor
  - 12.1.1.1 Drug Overview
  - 12.1.1.2 Mechanism of Action
  - 12.1.1.3 Clinical Trial Results
  - 12.1.1.4 Safety and Efficacy
  - 12.1.1.5 Regulatory Status
- 12.1.2 ATX01 - AlgoTherapeutix
  - 12.1.2.1 Drug Overview
  - 12.1.2.2 Mechanism of Action
  - 12.1.2.3 Clinical Trial Results
  - 12.1.2.4 Safety and Efficacy
  - 12.1.2.5 Regulatory Status
- 12.1.3 Tetrodotoxin - Wex Pharmaceuticals
  - 12.1.3.1 Drug Overview
  - 12.1.3.2 Mechanism of Action
  - 12.1.3.3 Clinical Trial Results
  - 12.1.3.4 Safety and Efficacy
  - 12.1.3.5 Regulatory Status
- 12.1.4 BXQ-350 - Bexion Pharmaceuticals
  - 12.1.4.1 Drug Overview
  - 12.1.4.2 Mechanism of Action
  - 12.1.4.3 Clinical Trial Results
  - 12.1.4.4 Safety and Efficacy
  - 12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

## **15 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034)
  - 15.2.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies
    - 15.2.2.1 Market Size by Therapies (2018-2023)
    - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size
    - 15.3.1.1 Market Size (2018-2023)
    - 15.3.1.2 Market Forecast (2024-2034)
  - 15.3.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (2018-2023)
    - 15.3.2.2 Market Forecast by Therapies (2024-2034)
  - 15.3.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement  
Overview

15.6 Market Scenario - United Kingdom

15.6.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

15.6.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies

15.6.2.1 Market Size by Therapies (2018-2023)

15.6.2.2 Market Forecast by Therapies (2024-2034)

15.6.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement  
Overview

15.7 Market Scenario - Italy

15.7.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size

15.7.1.1 Market Size (2018-2023)

15.7.1.2 Market Forecast (2024-2034)

15.7.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies

15.7.2.1 Market Size by Therapies (2018-2023)

15.7.2.2 Market Forecast by Therapies (2024-2034)

15.7.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement  
Overview

15.8 Market Scenario - Spain

15.8.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

15.8.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement  
Overview

15.9 Market Scenario - Japan

15.9.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size

15.9.1.1 Market Size (2018-2023)

15.9.1.2 Market Forecast (2024-2034)

15.9.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement Overview

## **16 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY MARKET - SWOT ANALYSIS**

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

## **18 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Chemotherapy-Induced Peripheral Neuropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/C44F9394C69BEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C44F9394C69BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

